Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4235
Structure:
Synonyms:
1A Brand of Moclobemide
4-Chlor-N-(2-morpholinoethyl)benzamid
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
71320-77-9
AC-12467
AC1L1HPM
AC1Q3IOZ
AKOS003270184
Alphapharm Brand of Moclobemide
Alpharma Brand of Moclobemide
Apo Moclobemide
Apo-Moclobemide
Apotex Brand of Moclobemide
Arima
Aurorex
Aurorix
Aurorix (TN)
AZU, Moclobemid
Azupharma Brand of Moclobemide
BAS 03214735
BC Brand of Moclobemide
BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-
betapharm Brand of Moclobemide
BIM-0048213.P001
BRN 0530974
Bull Brand of Moclobemide
C13H17ClN2O2
CBMicro_048319
CCG-100879
Chem mart Brand of Moclobemide
Chem mart Moclobemide
CHEMBL86304
CPD000012114
ct Arzneimittel Brand of Moclobemide
ct-Arzneimittel Brand of Moclobemide
D020912
D02561
DB01171
DBL Moclobemide
Deprenorm
esparma Brand of Moclobemide
Faulding Brand of Moclobemide
Feraken
GenRX Moclobemide
GNF-PF-695
Healthsense Brand of Moclobemide
Healthsense Moclobemide
Hexal Brand of Moclobemide
HMS2051A16
HMS2096G07
HMS2232B20
HMS3262F09
Hoffmann La Roche Brand of Moclobemide
Hoffmann-La Roche Brand of Moclobemide
HSDB 7180
Kendrick Brand of Moclobemide
LS-26161
Manerix
Merck dura Brand of Moclobemide
MLS000070549
MLS000759438
MLS001240195
Moclaime
Moclamide
Moclamine
Moclix
Moclobamide
Moclobemid
Moclobemid 1A Pharma
Moclobemid AZU
Moclobemid Puren
Moclobemid ratiopharm
Moclobemid Stada
Moclobemid von ct
Moclobemid-1A Pharma
Moclobemid-Puren
Moclobemid-ratiopharm
Moclobemid1A Pharma
Moclobemida
Moclobemida [INN-Spanish]
Moclobemide
Moclobemide (USAN/INN)
Moclobemide 1A Brand
Moclobemide Alphapharm Brand
Moclobemide Alpharma Brand
Moclobemide Apotex Brand
Moclobemide Azupharma Brand
Moclobemide BC Brand
Moclobemide betapharm Brand
Moclobemide Bull Brand
Moclobemide ct-Arzneimittel Brand
Moclobemide esparma Brand
Moclobemide Faulding Brand
Moclobemide Healthsense Brand
Moclobemide Hexal Brand
Moclobemide Kendrick Brand
Moclobemide Novopharm Brand
Moclobemide Nu-Pharm Brand
Moclobemide Pharmascience Brand
Moclobemide ratiopharm Brand
Moclobemide Roche Brand
Moclobemide Stadapharm Brand
Moclobemide Temmler Brand
Moclobemide [USAN:BAN:INN]
Moclobemide [USAN:INN:BAN]
Moclobemide, Chem mart
Moclobemide, DBL
Moclobemide, GenRX
Moclobemide, Healthsense
Moclobemidum
Moclobemidum [INN-Latin]
Moclobeta
Moclodura
Moclonorm
NCGC00027930-02
NCGC00027930-03
NCGC00027930-04
NCGC00027930-05
Novo Moclobemide
Novo-Moclobemide
NovoMoclobemide
Novopharm Brand of Moclobemide
Nu Moclobemide
Nu Pharm Brand of Moclobemide
Nu-Moclobemide
Nu-Pharm Brand of Moclobemide
NuMoclobemide
Oprea1_256739
Oprea1_270122
p-Chloro-N-(2-morpholinoethyl)benzamide
Pharmascience Brand of Moclobemide
PMS Moclobemide
PMS-Moclobemide
ratiopharm Brand of Moclobemide
Rimoc
Ro 11 1163
Ro 11-1163
Ro 11-1163/000
Ro-11-1163
Roche Brand of Moclobemide
SAM001246614
SMR000012114
ST50016353
Stada, Moclobemid
Stadapharm Brand of Moclobemide
STK222240
Temmler Brand of Moclobemide
Terry White Chemists Brand of Moclobemide
Terry White Chemists Moclobemide
von ct, Moclobemid
ZINC19606670
ATC-Codes:

Target

show target details
Uniprot ID:CP2CJ_HUMAN
Synonyms:
(R)-limonene 6-monooxygenase
(S)-limonene 6-monooxygenase
(S)-limonene 7-monooxygenase
CYPIIC17
CYPIIC19
Cytochrome P450 2C19
Mephenytoin 4-hydroxylase
P450-11A
P450-254C
EC-Numbers:1.14.13.48
1.14.13.49
1.14.13.80
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----
----
----

References:

012595913
11309556
Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.. K S Yu; D S Yim; J Y Cho; S S Park; J Y Park; K H Lee; I J Jang; S Y Yi; K S Bae; S G Shin (2001) Clinical pharmacology and therapeutics display abstract
BACKGROUND: Moclobemide, an antidepressant with selective monoamine oxidase-A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2. To confirm the involvement of CYP2C19, we performed a pharmacokinetic interaction study. METHODS: The effect of omeprazole on the pharmacokinetics of moclobemide was studied in 16 healthy volunteers. The volunteer group comprised 8 extensive metabolizers and 8 poor metabolizers of CYP2C19, which was confirmed by genotyping. Subjects were randomly allocated into two sequence groups, and a single-blind, placebo-controlled, two-period crossover study was performed. In study I, a placebo was orally administered for 7 days. On the eighth morning, 300 mg of moclobemide and 40 mg of placebo were coadministered with 200 mL of water, and a pharmacokinetic study was performed. During study II, 40 mg of omeprazole was given each morning instead of placebo, and pharmacokinetic studies were performed on the first and eighth day with 300 mg of moclobemide coadministration. RESULTS: The inhibition of moclobemide metabolism was significant in extensive metabolizers even after a single dose of omeprazole. After daily administration of omeprazole for 1 week, the pharmacokinetic parameters of moclobemide and its metabolites in extensive metabolizers changed to values similar to those in poor metabolizers. In poor metabolizers, no remarkable changes in the pharmacokinetic parameters were observed. CONCLUSION: Our results show that CYP2C19 is an important enzyme in the elimination of moclobemide and that it is extensively inhibited by omeprazole in extensive metabolizers, but not in poor metabolizers.
11966672
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.. Joo-Youn Cho; Kyung-Sang Yu; In-Jin Jang; Byung-Hwan Yang; Sang-Goo Shin; Dong-Seok Yim (2002) British journal of clinical pharmacology display abstract
AIMS: The pharmacokinetics of omeprazole and its metabolites in healthy subjects were evaluated to determine if a single dose of moclobemide inhibited CYP2C19 activity. METHODS: Sixteen volunteers, of whom eight were extensive metabolizers (EM) and eight were poor metabolizers for CYP2C19, participated in two studies. Venous blood samples were collected for 24 h after oral ingestion of 40 mg omeprazole with or without 300 mg moclobemide coadministration. The pharmacokinetic change of omeprazole, omeprazole sulphone and 5-hydroxyomeprazole concentrations were assessed to test for an interaction between omeprazole and moclobemide. RESULTS: The coadministration of moclobemide in EMs approximately doubled the mean AUC (from 1834 to 3760 ng ml(-1) h) and C(max) (from 987 to 1649 ng ml(-1)) of omeprazole, and increased the AUC of omeprazole sulphone without changing AUC ratio of omeprazole to omeprazole sulphone. Moclobemide coadministration more than doubled the AUC ratio of omeprazole to 5-hydroxyomeprazole (from 2.5 to 5.3) in EMs, too. There was a significant decrease in Cmax and AUC of 5-hydroxyomeprazole in PMs but no significant changes were seen in the results for omeprazole and omeprazole sulphone AUCs. CONCLUSIONS: A single dose of moclobemide resulted in significant suppression of CYP2C19 activity in EMs. We conclude that physicians prescribing moclobemide should pay attention to its pharmacokinetic interactions even on the first day of coadministration with CYP2C19 substrates.
7781267
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.. L F Gram; T W Guentert; S Grange; K Vistisen; K BrÝsen (1995) Clinical pharmacology and therapeutics display abstract
The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8). All were extensive metabolizers of sparteine. Poor metabolizers of S-mephenytoin had lower moclobemide clearance values (median, single dose: 16.1 versus 43.2 L.hr-1; steady state: 13.4 versus 22.1 L.hr-1) and longer moclobemide half-life values (median, single dose: 4.0 versus 1.8 hours; steady state: 5.1 versus 2.7 hours) than extensive metabolizers of S-mephenytoin. The plasma levels of a metabolite formed by C-hydroxylation (Ro 12-8095) were lower in poor metabolizers of S-mephenytoin than in extensive metabolizers of S-mephenytoin. Moclobemide thus partially undergoes oxidative metabolism by way of the polymorphic CYP2C19. A combined mephenytoin, sparteine, and caffeine test performed before, during, and after multiple dosing of moclobemide showed changes in the metabolic indexes compatible with a reversible inhibition of oxidation by way of the corresponding CYP enzymes--CYP2C19, CYP2D6, and CYP1A2--during moclobemide treatment.
9265947